As regards to Dabur Pharma ,Tarun Sisodia, of Anand Rathi Securities observes that the company has arrested the decline in the profits, which was a major concern about three quarters back. Secondly, last quarter, it grew by about 10% in terms of bottomline, he says.
He says, " Dabur Pharma has done two things - It has arrested the decline in the profits, which was a major concern in that company about three quarters back. Secondly, last quarter, it grew by about 10% in terms of bottomline."
He further states, "This is the quarter, where they are clearly indicating that they are braving out into their high growth stage. We have seen roughly about 33-34% growth rate in the topline out here, of which the bulk drugs have contributed about 46% whereas the formulation is a very healthy 32% growth rate."
He adds, "The operating margins have jumped up quite significantly from 8% to 10% level, again indicating the scale benefits in terms of other expenses as a percentage of sales going down. From 41%, it has fallen down to 38%."
"This has resulted in overall profit growth rate of 49%. So, I think there is a significant thrill in the fact that the company has not only arrested the decline but has gone into a very high growth path, though on valuation basis, this stock still looks very expensive," he states.
He says, " 
